Catenacci, D. V., Liao, C.-Y., Maron, S., Solomon, B. J., Mahipal, A., Johnson, M. L., Carbone, D., Henick, B. S., Johnson, B., Roychowdhury, S., Mody, K., Ahn, D. H., Bournazou, E., Schenk, D., Kounlavouth, S., Kraemer, L., Talbot, G., Rousseau, R., Ferguson, A. R., & Spira, A. (2021). 960MO Clinical outcomes and immune responses in a phase I/II study of personalized, neoantigen-directed immunotherapy in patients with advanced MSS-CRC, GEA and NSCLC. Annals of Oncology, 32, S830–S831. https://doi.org/10.1016/j.annonc.2021.08.1345